VTGN News and Press, VistaGen Therapeutics Inc. From 12/18/20

Can These 5 Penny Stocks Continue to Rally? Throughout the month of December, investors have seen a lot of positive sentiment with penny stocks . While trading these stocks has changed in 2020, the majority of the factors remain largely the same. This includes understanding the fund...

VistaGen Therapeutics (VTGN) has priced 63M common shares at $0.92/share and 2M shares of its Series D convertible preferred stock at $21.16/share, for gross proceeds of $100M. Each share of the Series D Preferred Stock will be initially convertible into 23 common shares at any time at the ho...

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central ner...

VistaGen Therapeutics (VTGN) -16.8% AH, commenced an underwritten public offering of units consisting of its common stock, par value $0.001/share and its Series D convertible preferred stock.Terms, actual size have not yet been disclosed.Series D Preferred Stock will be initially convert...

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central ner...

VistaGen Therapeutics (VTGN) announces that the Korean Intellectual Property Office has issued a Decision to Grant Patent Application No. 10-2015-7020176 related to methods of treating depressive disorder with VistaGen's PH10.The patent is not set to expire earlier than 2034.PH10 is an invest...

VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of Depression SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation me...

VistaGen Therapeutics Expands R&D Team with Appointment of Louis Monti, M.D., Ph.D., Pioneer in the Development of Neuroactive Steroids known as Pherines as Potential Treatments for Anxiety and Depression Disorders, as Vice President, Translational Medicine VistaGen Therapeu...

VistaGen Therapeutics (VTGN): Q2 EPS of -$0.05 may not be comparable to consensus of -$0.01.Revenue of $0.33MPress Release For further details see: VistaGen Therapeutics EPS of -$0.05

VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress Positive FDA Meeting Sets Key Pathway for Pivotal PH94B Phase 3 Study in the Second Quarter of 2021 Received Over $17.5 Million Net Pr...